Erste Asset Management Gmb H Selecta Biosciences Inc Transaction History

Erste Asset Management Gmb H

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Nov 26, 2024	SELL	N/A	-3,212,093 Closed	0 $0
Q1 2024 Nov 26, 2024	BUY	$0.62 - $0.85 $52,757 - $72,329	85,093 Added 2.72%	3,212,093 $2.09 Billion
Q4 2023 Nov 26, 2024	BUY	$0.67 - $1.35 $402,000 - $810,000	600,000 Added 23.74%	3,127,000 $2.16 Billion
Q3 2023 Nov 26, 2024	BUY	$1.02 - $1.23 $459,000 - $553,500	450,000 Added 21.67%	2,527,000 $2.69 Billion
Q2 2023 Nov 26, 2024	BUY	$1.04 - $1.4 $260,000 - $350,000	250,000 Added 12.04%	2,327,000 $2.61 Billion
Q4 2022 Nov 26, 2024	SELL	$0.96 - $1.6 $480,000 - $800,000	-500,000 Reduced 19.4%	2,077,000 $2.35 Billion
Q3 2022 Nov 26, 2024	BUY	$1.33 - $2.6 $2.76 Million - $5.4 Million	2,077,000 New	2,077,000 $3.4 Billion
Q2 2022 Nov 26, 2024	BUY	$0.67 - $1.4 $1.73 Million - $3.61 Million	2,577,000 New	2,577,000 $3.37 Billion
Q1 2022 Nov 22, 2024	BUY	$1.23 - $3.31 $2.49 Million - $6.71 Million	2,027,000 New	2,027,000 $2.5 Billion
Q4 2021 Nov 22, 2024	BUY	$2.89 - $4.43 $3.5 Million - $5.36 Million	1,210,000 New	1,210,000 $4.04 Billion

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.